Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

35.3%

6 terminated/withdrawn out of 17 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

12%

2 trials in Phase 3/4

Results Transparency

50%

5 of 10 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2
8(50.0%)
Phase 1
6(37.5%)
Phase 3
2(12.5%)
16Total
Phase 2(8)
Phase 1(6)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT04614467Phase 2Terminated

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

Role: lead

NCT05712356Phase 2Active Not Recruiting

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Role: lead

NCT06592664Phase 1Withdrawn

Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

Role: lead

NCT04522817Phase 1Withdrawn

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

Role: lead

NCT04990427Phase 1Completed

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

Role: lead

NCT02501018Phase 2Completed

Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)

Role: lead

NCT03517176Phase 1Completed

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Role: lead

NCT00014131Phase 1Terminated

Vaccine Therapy in Treating Patients With Kidney Cancer

Role: lead

NCT00300053Phase 2Completed

ACT34-CMI -- Adult Autologous CD34+ Cells

Role: lead

NCT02691247Phase 2Completed

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

Role: lead

NCT03508609Phase 2Completed

Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Role: lead

NCT00814593Phase 2Withdrawn

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

Role: lead

NCT01875653Phase 3Terminated

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Role: lead

NCT01508910Phase 3Completed

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Role: lead

NCT00545610Completed

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

Role: lead

NCT01495364Phase 2Completed

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

Role: lead

NCT00012064Phase 1Completed

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

Role: lead

All 17 trials loaded